Logo image of ALDVI.PA

ADVICENNE (ALDVI.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALDVI - FR0013296746 - Common Stock

1.74 EUR
-0.01 (-0.57%)
Last: 12/5/2025, 7:00:00 PM
Fundamental Rating

1

ALDVI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALDVI have multiple concerns. ALDVI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALDVI had negative earnings in the past year.
In the past 5 years ALDVI always reported negative net income.
In the past 5 years ALDVI always reported negative operating cash flow.
ALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

ALDVI's Return On Assets of -96.03% is on the low side compared to the rest of the industry. ALDVI is outperformed by 87.04% of its industry peers.
Industry RankSector Rank
ROA -96.03%
ROE N/A
ROIC N/A
ROA(3y)-69.72%
ROA(5y)-67.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALDVI.PA Yearly ROA, ROE, ROICALDVI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

ALDVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDVI.PA Yearly Profit, Operating, Gross MarginsALDVI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ALDVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALDVI remains at a similar level compared to 1 year ago.
ALDVI has more shares outstanding than it did 5 years ago.
ALDVI has a worse debt/assets ratio than last year.
ALDVI.PA Yearly Shares OutstandingALDVI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALDVI.PA Yearly Total Debt VS Total AssetsALDVI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -12.32, we must say that ALDVI is in the distress zone and has some risk of bankruptcy.
ALDVI's Altman-Z score of -12.32 is on the low side compared to the rest of the industry. ALDVI is outperformed by 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.32
ROIC/WACCN/A
WACC7.13%
ALDVI.PA Yearly LT Debt VS Equity VS FCFALDVI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

ALDVI has a Current Ratio of 0.59. This is a bad value and indicates that ALDVI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.59, ALDVI is doing worse than 88.89% of the companies in the same industry.
A Quick Ratio of 0.45 indicates that ALDVI may have some problems paying its short term obligations.
ALDVI has a Quick ratio of 0.45. This is amonst the worse of the industry: ALDVI underperforms 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.45
ALDVI.PA Yearly Current Assets VS Current LiabilitesALDVI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.14% over the past year.
The Revenue has been growing slightly by 4.75% in the past year.
The Revenue has been growing by 9.63% on average over the past years. This is quite good.
EPS 1Y (TTM)14.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.3%
Revenue 1Y (TTM)4.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y9.63%
Sales Q2Q%67.79%

3.2 Future

Based on estimates for the next years, ALDVI will show a very strong growth in Earnings Per Share. The EPS will grow by 25.63% on average per year.
ALDVI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.89% yearly.
EPS Next Y17.08%
EPS Next 2Y27.95%
EPS Next 3Y25.63%
EPS Next 5YN/A
Revenue Next Year54.05%
Revenue Next 2Y39.5%
Revenue Next 3Y37.89%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALDVI.PA Yearly Revenue VS EstimatesALDVI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
ALDVI.PA Yearly EPS VS EstimatesALDVI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALDVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALDVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDVI.PA Price Earnings VS Forward Price EarningsALDVI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDVI.PA Per share dataALDVI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ALDVI's earnings are expected to grow with 25.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.95%
EPS Next 3Y25.63%

More info and screens

0

5. Dividend

5.1 Amount

ALDVI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVICENNE

EPA:ALDVI (12/5/2025, 7:00:00 PM)

1.74

-0.01 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-25 2025-07-25
Earnings (Next)03-25 2026-03-25/amc
Inst Owners18.74%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.74M
Revenue(TTM)2.63M
Net Income(TTM)-6.46M
Analysts84.44
Price Target4.08 (134.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.2%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.19
BVpS-1.69
TBVpS-1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.72%
ROA(5y)-67.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.45
Altman-Z -12.32
F-ScoreN/A
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.3%
EPS Next Y17.08%
EPS Next 2Y27.95%
EPS Next 3Y25.63%
EPS Next 5YN/A
Revenue 1Y (TTM)4.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y9.63%
Sales Q2Q%67.79%
Revenue Next Year54.05%
Revenue Next 2Y39.5%
Revenue Next 3Y37.89%
Revenue Next 5YN/A
EBIT growth 1Y-34.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.91%
EBIT Next 3Y31.15%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ADVICENNE / ALDVI.PA FAQ

What is the ChartMill fundamental rating of ADVICENNE (ALDVI.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALDVI.PA.


What is the valuation status of ADVICENNE (ALDVI.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to ADVICENNE (ALDVI.PA). This can be considered as Overvalued.


How profitable is ADVICENNE (ALDVI.PA) stock?

ADVICENNE (ALDVI.PA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ADVICENNE?

The Earnings per Share (EPS) of ADVICENNE (ALDVI.PA) is expected to grow by 17.08% in the next year.